Abstract:
Background: Mushrooms inspired the cuisines of many cultures and conventional medicaments for cancer.
However, a substantial number of mushroom species are yet unexplored, possessing an unknown chemical,
biological and pharmacological profiles. Fulviformes fastuosus is a terrestrial mushroom, which is commonly found in
Sri Lankan woodlands. The current study was aimed at isolation and characterization of a potent cytotoxic
compound from F. fastuosus and investigating the apoptotic effect induced by the active principle against cancer
and normal cell lines.
Methods: Bioactivity guided isolation of active principles from the methanol extract of F. fastuosus was performed
by a rapid extraction and isolation method using different chromatographic techniques. Potential cytotoxic
compound was identified using one and two dimensional nuclear magnetic resonance spectroscopy and mass
spectrometry. Isolated compound was screened for in vitro cytotoxicity against Hepatocellular carcinoma (HepG-2),
Muscle rhabdomyosarcoma (RD) and Rat Wistar liver normal (CC-1) cell lines using 3 4, 5-(dimethylthiazol-2-yl) 2-5-
diphenyl tetrazolium bromide (MTT) cell viability assay. Apoptotic features of cells were observed via microscopic
examination and ethidium bromide/acridine orange fluorescent staining.
Results: The interpretation of spectral data resulted in the identification of the chemical structure as ergosta-4,6,8
(14),22-tetraen-3-one (ergone). Ergone exhibited promising cytotoxic properties against RD cells with less
cytotoxicity effect on CC-1 cells. In addition, ergone also possesses a strong cytotoxic effect against HepG-2 cells
showing low toxic level for CC-1 cells. Apoptotic features of treated cells were detected via morphological
characterization and ethidium bromide/acridine orange staining.
Conclusion: The present study elaborates the isolation of a potent cytotoxic compound; ergone, from F. fastuosus
via a rapid and efficient isolation method. Importantly, ergone has exhibited greater cytotoxic activity against RD
cells with high selectivity index compared to cytotoxicity against HepG-2 cells. Ergone can be used in the
development of therapeutic strategies for curbing rhabdomyosarcoma.